AMAG Pharma (AMAG) Reports Q4 Loss of $5.89/Share

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/2/2026

1. CRWD
2. REGN
3. ABBV
4. CL
5. LYB
6. TFII
7. SPY
8. AAPL
9. LITE
10. NVT

Go back to AMAG Pharma (AMAG) Reports Q4 Loss of $5.89/Share

AMAG Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update

March 4, 2020 7:00 AM EST

WALTHAM, Mass., March 04, 2020 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today reported unaudited consolidated financial results for the fourth quarter and full year ended December 31, 2019. Total revenues for the full year of 2019 totaled $327.8 million, including revenue of $167.9 million from Feraheme® (ferumoxytol injection), revenue of $122.1 million from Makena® (hydroxyprogesterone caproate injection), and revenue of $21.4 million from Intrarosa® (prasterone). The company reported an operating loss of $445.5 million and an adjusted EBITDA loss of $65.0 million in 2019.1

Our financial results reported today reflect the successes and challenges of 2019. While we achieved record revenue... More